Answers are grounded in this paper and cite their sources.
Objectives Breast cancer (BC) is a major global health issue as it is the most common malignancy in women. Despite, the role of neoadjuvant chemotherapy (NAC) in early BC has been established, there is a non-small proportion of patients who might develop chemoresistance. Several studies have investigated the relationship between microRNA-210 (miRNA-210) and neoadjuvant chemoresistance in BC with controversial results. Thus, this study aimed to evaluate the role of miRNA-210 as a predictor for chemoresistance in BC receiving NAC. Material and Methods The study enrolled 15 chemo-sensitive and 15 chemo-resistant patients with BC receiving NAC. In addition, 10 newly-diagnosed BC patients before treatment and 10 healthy women were recruited as controls. Serum samples from all patients and controls were withdrawn and measurements of miRNA-210 levels using quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) were done and compared. Results The median value of miRNA-210 level was 1.53, 0.27, 0.52, and 1.35 in chemo-sensitive, chemo-resistant, newly-diagnosed, and control groups, respectively. A statistically significant difference (Chi square = 9.801, p = 0.020, df = 3) was found in the mean serum miRNA-210 among the four different groups. Using logistic regression model, low serum miRNA-210 expression level was found to be a predictive factor of chemo-resistance with p = 0.038 (OR of 0.103, 95% CI = 0.012 –0.886). Using the receiver operating characteristic curve, it was found that the area under the curve (AUC) was 0.747 (95% CI = 0.550 –0.943). Conclusion Serum miRNA-210 could be an effective predictive biomarker for chemoresistance in BC patients receiving NAC.
No takes yet. Share an insight, caveat, or question.
Naeem et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: